TheraVet announces the signing of a new agreement for the BIOCERA-VET® range with Elvetis, specialist in the distribution of animal health products
This agreement allows TheraVet to refocus its efforts on its network of high-potential clinics by relying on a specialized distributor with its own sales force in France.
Gosselies (Wallonia, Belgium), December 12, 2022 – 7:30 a.m. CET — TheraVet (ISIN code: BE0974387194 – mnemonic: ALVET), a pioneering biotechnology company in the treatment of bone and joint diseases in pets, today announces the signing of a new exclusive distribution agreement for its line of BIOCERA-VET® bone substitutes in France with Elvetis, one of the main specialists in animal health products in France. The entire range, namely BIOCERA-VET® Bone Surgery (BS) RTU, BIOCERA-VET® BS Granules, BIOCERA-VET® BS SmartGraft and BIOCERA-VET® Osteosarcoma RTU, is concerned by this agreement.
To receive all of TheraVet’s financial information in real time, send a request by email to [email protected]